MX2023001233A - Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab, un taxano y un antagonista del vegfr-2. - Google Patents
Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab, un taxano y un antagonista del vegfr-2.Info
- Publication number
- MX2023001233A MX2023001233A MX2023001233A MX2023001233A MX2023001233A MX 2023001233 A MX2023001233 A MX 2023001233A MX 2023001233 A MX2023001233 A MX 2023001233A MX 2023001233 A MX2023001233 A MX 2023001233A MX 2023001233 A MX2023001233 A MX 2023001233A
- Authority
- MX
- Mexico
- Prior art keywords
- tucatinib
- taxane
- vegfr
- trastuzumab
- antagonist
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 229940123237 Taxane Drugs 0.000 title abstract 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title abstract 2
- 229960000575 trastuzumab Drugs 0.000 title abstract 2
- 229950003463 tucatinib Drugs 0.000 title abstract 2
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 title 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 title 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 abstract 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente descripción está relacionada con un método de tratamiento de un cáncer positivo para HER2 en un sujeto que lo necesite, donde el método comprende administrar al sujeto una cantidad con eficacia terapéutica de una terapia combinada que comprende tucatinib, trastuzumab, un taxano y un antagonista del VEGFR-2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063058146P | 2020-07-29 | 2020-07-29 | |
| PCT/US2021/043395 WO2022026510A1 (en) | 2020-07-29 | 2021-07-28 | Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab, a taxane, and a vegfr-2 antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001233A true MX2023001233A (es) | 2023-03-02 |
Family
ID=77666547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001233A MX2023001233A (es) | 2020-07-29 | 2021-07-28 | Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab, un taxano y un antagonista del vegfr-2. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230270745A1 (es) |
| EP (1) | EP4188384A1 (es) |
| JP (1) | JP2023537676A (es) |
| KR (1) | KR20230047359A (es) |
| CN (1) | CN116723858A (es) |
| AU (1) | AU2021315520A1 (es) |
| CA (1) | CA3189333A1 (es) |
| IL (1) | IL300052A (es) |
| MX (1) | MX2023001233A (es) |
| WO (1) | WO2022026510A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024089702A1 (en) * | 2022-10-28 | 2024-05-02 | Natco Pharma Limited | An improved process for the preparation of tucatinib and its salt & polymorphs thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| RS56608B1 (sr) | 2011-10-14 | 2018-02-28 | Array Biopharma Inc | Čvrsta disperzija |
| WO2013056183A1 (en) | 2011-10-14 | 2013-04-18 | Array Biopharma Inc. | Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them |
| EP2847226A4 (en) * | 2012-05-11 | 2016-05-11 | Merrimack Pharmaceuticals Inc | DOSAGE AND ADMINISTRATION OF BIS SPECIFIC SCFV CONJUGATES IN COMBINATION WITH ANTICROBIAL AGENTS |
-
2021
- 2021-07-28 MX MX2023001233A patent/MX2023001233A/es unknown
- 2021-07-28 AU AU2021315520A patent/AU2021315520A1/en active Pending
- 2021-07-28 IL IL300052A patent/IL300052A/en unknown
- 2021-07-28 WO PCT/US2021/043395 patent/WO2022026510A1/en active Application Filing
- 2021-07-28 EP EP21766544.7A patent/EP4188384A1/en active Pending
- 2021-07-28 JP JP2023503434A patent/JP2023537676A/ja active Pending
- 2021-07-28 CN CN202180060011.7A patent/CN116723858A/zh active Pending
- 2021-07-28 KR KR1020237001749A patent/KR20230047359A/ko unknown
- 2021-07-28 CA CA3189333A patent/CA3189333A1/en active Pending
- 2021-07-28 US US18/017,905 patent/US20230270745A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023537676A (ja) | 2023-09-05 |
| EP4188384A1 (en) | 2023-06-07 |
| US20230270745A1 (en) | 2023-08-31 |
| KR20230047359A (ko) | 2023-04-07 |
| IL300052A (en) | 2023-03-01 |
| WO2022026510A1 (en) | 2022-02-03 |
| CN116723858A (zh) | 2023-09-08 |
| AU2021315520A1 (en) | 2023-02-09 |
| CA3189333A1 (en) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551908A1 (en) | Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics | |
| MX2020008977A (es) | Formulaciones de anticuerpos de her2 subcutaneas. | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| MX2020012799A (es) | Composicion y metodo para tratar el cancer asociado con mutacion del egfr. | |
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| MX2023002554A (es) | Anticuerpos anti-il-1r3 humanizados. | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX2023006793A (es) | Tratamientos conjuntos para tratamiento de cancer her2. | |
| MX2023004156A (es) | Terapia combinada para el tratamiento del cancer. | |
| MX2022005903A (es) | Métodos para tratar el cáncer de mama her2 positivo con tucatinib en combinación con un conjugado fármaco-anticuerpo anti-her2. | |
| MX2022004699A (es) | Metodos de tratamiento del cancer de mama con sobreexpresion de her2 con tucatinib en combinacion con capecitabina y trastuzumab. | |
| MX2023001233A (es) | Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab, un taxano y un antagonista del vegfr-2. | |
| PH12021551276A1 (en) | Combination therapy for the treatment of cancer | |
| MX2021007565A (es) | Composiciones y metodos para la terapia contra el cancer. | |
| MX2022014886A (es) | Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino. | |
| MX2021004207A (es) | Uso de reboxetina para el tratamiento de narcolepsia. | |
| MX2021001832A (es) | Conjugados para su uso en metodos de tratamiento del cancer. | |
| PH12021551235A1 (en) | Elacestrant in combination with abemaciclib in women with breast cancer | |
| ZA201907754B (en) | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer | |
| MX2022001450A (es) | Metodo de tratamiento del cancer. | |
| MX2021010228A (es) | Administracion de inhibidores de pd-1 para el tratamiento de cancer de piel. | |
| ZA202201446B (en) | Methods of treating multifocal cancer | |
| PH12020550066A1 (en) | METHOD FOR TREATING TNFa-RELATED DISEASE | |
| MX2022001411A (es) | Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5. | |
| JOP20220073A1 (ar) | استخدام مثبطات fgfr في السرطانات المعدلة جينيا بـ fgfr لتحسين استجابة المريض لتحصين مثبطات نقطة الفحص في أوضاع علاجية تتابعية |